

PROLIGHT RECEIVES NOTICE OF ALLOWANCE IN JAPAN FOR CORE PATENT RELATED TO PSYROS™ TECHNOLOGY

Prolight Diagnostics announces today that the company have received a notice of allowance from the Japanese Patent office for their primary patent application related to the Psyros single-molecule-counting technology. This is the second territory to allow this application, following grant by the European Patent Office earlier this year.

"We are delighted to have another territory allow this application relating to the core Psyros technology as we continue to build a robust IP portfolio. Japan represents one of the largest markets globally for in vitro diagnostics (IVD). Robust patent protection paves the way for strategic partnerships and positions the company for future platform expansion," said Ulf Bladin, CEO of Prolight Diagnostics.

This patent application (JP 2021-576910) protects the fundamental measurement system used in the Psyros single-molecule-counting technology. The system uses photoactive reporter molecules to permanently bleach dark spots in a fluorescent layer, with each spot representing a single binding event. A number of formalities will now take place before the process is complete and the patent is fully granted by the Japanese Patent Office.

"Patent approval in Japan can often be complex and we are particularly pleased to have navigated this process so rapidly. This patent has been allowed straight after our response to the first office action from the Japanese Patent Office, which reaffirms the uniqueness of our technology," said Steve Ross, CTO of Prolight Diagnostics, responsible for managing the IP portfolio.

Prolight currently have six families of patent applications relating to the Psyros single-molecule-counting technology. The first three are currently in the national / regional phases in a range of territories worldwide. Families four and five are in the PCT phase and will enter the national / regional phases later this year. The sixth is a priority application in the UK. The first two patents were granted in Europe earlier this year and are being validated in 17 countries across Europe.

For further information, please contact:

Ulf Bladin, CEO

E-mail: info@prolightdx.com

Phone: +46 73 582 39 87

Company website: www.prolightdx.com

About Us

Prolight Diagnostics AB develops innovative Point-of-Care systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of high sensitive troponin, to aid in the rule-in and rule-out of myocardial infarction.

The company's share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

Attachments

Prolight receives notice of allowance in Japan for core patent related to Psyros™ technology